| Schedule of Assets and Liabilities Measured at Fair Value |
The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at March 31, 2026: | | | | | | | | | | | | | | | | | | | | | | | | | Total | | Quoted
prices in
active
markets
(Level 1) | | Significant
other
observable
inputs
(Level 2) | | Significant
unobservable
inputs
(Level 3) | | | (in thousands) | | Assets: | | | | | | | | | Deferred compensation plan investments, current and non-current | $ | 33,981 | | | $ | 33,981 | | | $ | — | | | $ | — | | | Forward foreign currency exchange contracts | 13 | | | — | | | 13 | | | — | | | Interest rate swap agreement | 153 | | | — | | | 153 | | | — | | | | | | | | | | | Total assets at fair value | $ | 34,147 | | | $ | 33,981 | | | $ | 166 | | | $ | — | | | Liabilities: | | | | | | | | | Deferred compensation plan investments, current and non-current | $ | 33,981 | | | $ | 33,981 | | | $ | — | | | $ | — | | | | | | | | | | | Foreign currency hedge | 43 | | | — | | | 43 | | | — | | | | | | | | | | | Liability for contingent consideration, current and non-current | 29,040 | | | — | | | — | | | 29,040 | | | Total liabilities at fair value | $ | 63,064 | | | $ | 33,981 | | | $ | 43 | | | $ | 29,040 | |
The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at June 30, 2025: | | | | | | | | | | | | | | | | | | | | | | | | | Total | | Quoted
prices in
active
markets
(Level 1) | | Significant
other
observable
inputs
(Level 2) | | Significant
unobservable
inputs
(Level 3) | | | (in thousands) | | Assets: | | | | | | | | | Deferred compensation plan investments, current and non-current | $ | 31,887 | | | $ | 31,887 | | | $ | — | | | $ | — | | | Forward foreign currency exchange contracts | 15 | | | — | | | 15 | | | — | | | Interest rate swap agreement | 680 | | | — | | | 680 | | | — | | | | | | | | | | | Total assets at fair value | $ | 32,582 | | | $ | 31,887 | | | $ | 695 | | | $ | — | | | Liabilities: | | | | | | | | | Deferred compensation plan investments, current and non-current | $ | 31,887 | | | $ | 31,887 | | | $ | — | | | $ | — | | | | | | | | | | | Foreign currency hedge | 290 | | | — | | | 290 | | | — | | | Liability for contingent consideration, current and non-current | 19,100 | | | — | | | — | | | 19,100 | | | Total liabilities at fair value | $ | 51,277 | | | $ | 31,887 | | | $ | 290 | | | $ | 19,100 | |
|
| Schedule of Changes in Fair Value of Contingent Considerations |
The following tables summarize the fair value of the Company's contingent consideration liabilities at March 31, 2026 and March 31, 2025: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Contingent consideration for the quarter ended | | Contingent consideration for the nine months ended | | March 31, 2026 | | March 31, 2026 | | | Specialty Technology Solutions | | Intelisys & Advisory | | Total | | Specialty Technology Solutions | | Intelisys & Advisory | | Total | | | (in thousands) | | Fair value at beginning of period | $ | 15,910 | | | $ | 12,690 | | | $ | 28,600 | | | $ | 6,660 | | | $ | 12,440 | | | $ | 19,100 | | | Issuance of contingent consideration | — | | | — | | | — | | | 9,352 | | | — | | | 9,352 | | | Payments | — | | | — | | | — | | | (1,375) | | | — | | | (1,375) | | | | | | | | | | | | | | | Change in fair value of contingent consideration | 410 | | | 30 | | | 440 | | | 1,683 | | | 280 | | | 1,963 | | | | | | | | | | | | | | | Fair value at end of period | $ | 16,320 | | | $ | 12,720 | | | $ | 29,040 | | | $ | 16,320 | | | $ | 12,720 | | | $ | 29,040 | | | | | | | | | | | | | | | Contingent consideration for the quarter ended | | Contingent consideration for the nine months ended | | March 31, 2025 | | March 31, 2025 | | Specialty Technology Solutions | | Intelisys & Advisory | | Total | | Specialty Technology Solutions | | Intelisys & Advisory | | Total | | (in thousands) | | Fair value at beginning of period | $ | 7,973 | | | $ | 10,370 | | | $ | 18,343 | | | $ | — | | | $ | — | | | $ | — | | | Issuance of contingent consideration | — | | | — | | | — | | | 7,500 | | | 9,700 | | | 17,200 | | | | | | | | | | | | | | | | | | | | | | | | | | | Change in fair value of contingent consideration | 94 | | | 810 | | | 904 | | | 567 | | | 1,480 | | | 2,047 | | | | | | | | | | | | | | | Fair value at end of period | $ | 8,067 | | | $ | 11,180 | | | $ | 19,247 | | | $ | 8,067 | | | $ | 11,180 | | | $ | 19,247 | |
Significant observable inputs used in recurring Level 3 fair value measurements for the Company's contingent consideration liabilities by segment related to acquisitions at March 31, 2026 and March 31, 2025 were as follows. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Significant observable inputs | | Significant observable inputs | | | March 31, 2026 | | March 31, 2025 | | Acquisition | | Specialty Technology Solutions | | Intelisys & Advisory | | Specialty Technology Solutions | | Intelisys & Advisory | | Weighted-average payor credit spread | | 1.89 | % | | 1.90 | % | | 2.00 | % | | 2.00 | % | | Weighted-average adjusted EBITDA risk premium | | 12.30 | % | | 12.10 | % | | 15.00 | % | | 12.90 | % | | Adjusted EBITDA volatility | | 60.00 | % | | 45.00 | % | | — | | | 40.00 | % |
|